Wistuba II - Search Results

1

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.

Cascone T, William WN Jr, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G Jr, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Cascone T, et al. Among authors: wistuba ii. Nat Med. 2021 Mar;27(3):504-514. doi: 10.1038/s41591-020-01224-2. Epub 2021 Feb 18. Nat Med. 2021. PMID: 33603241 Free PMC article. Clinical Trial.

2

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF. Shigematsu H, et al. Among authors: wistuba ii. J Natl Cancer Inst. 2005 Mar 2;97(5):339-46. doi: 10.1093/jnci/dji055. J Natl Cancer Inst. 2005. PMID: 15741570

3

Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.

Wislez M, Spencer ML, Izzo JG, Juroske DM, Balhara K, Cody DD, Price RE, Hittelman WN, Wistuba II, Kurie JM. Wislez M, et al. Among authors: wistuba ii. Cancer Res. 2005 Apr 15;65(8):3226-35. doi: 10.1158/0008-5472.CAN-04-4420. Cancer Res. 2005. PMID: 15833854

4

EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients.

Tang X, Shigematsu H, Bekele BN, Roth JA, Minna JD, Hong WK, Gazdar AF, Wistuba II. Tang X, et al. Among authors: wistuba ii. Cancer Res. 2005 Sep 1;65(17):7568-72. doi: 10.1158/0008-5472.CAN-05-1705. Cancer Res. 2005. PMID: 16140919

5

High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.

Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna AE, Kalyankrishna S, Cody DD, Price RE, Sato M, Shay JW, Minna JD, Peyton M, Tang X, Massarelli E, Herbst R, Threadgill DW, Wistuba II, Kurie JM. Fujimoto N, et al. Among authors: wistuba ii. Cancer Res. 2005 Dec 15;65(24):11478-85. doi: 10.1158/0008-5472.CAN-05-1977. Cancer Res. 2005. PMID: 16357156

6

High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras.

Wislez M, Fujimoto N, Izzo JG, Hanna AE, Cody DD, Langley RR, Tang H, Burdick MD, Sato M, Minna JD, Mao L, Wistuba I, Strieter RM, Kurie JM. Wislez M, et al. Cancer Res. 2006 Apr 15;66(8):4198-207. doi: 10.1158/0008-5472.CAN-05-3842. Cancer Res. 2006. PMID: 16618742

7

Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions.

Tang X, Liu D, Shishodia S, Ozburn N, Behrens C, Lee JJ, Hong WK, Aggarwal BB, Wistuba II. Tang X, et al. Among authors: wistuba ii. Cancer. 2006 Dec 1;107(11):2637-46. doi: 10.1002/cncr.22315. Cancer. 2006. PMID: 17078054 Free article.

8

Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry.

Shen J, Behrens C, Wistuba II, Feng L, Lee JJ, Hong WK, Lotan R. Shen J, et al. Among authors: wistuba ii. Cancer Res. 2006 Dec 1;66(23):11194-206. doi: 10.1158/0008-5472.CAN-04-1444. Cancer Res. 2006. PMID: 17145864

9

Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway.

Xia D, Srinivas H, Ahn YH, Sethi G, Sheng X, Yung WK, Xia Q, Chiao PJ, Kim H, Brown PH, Wistuba II, Aggarwal BB, Kurie JM. Xia D, et al. Among authors: wistuba ii. J Biol Chem. 2007 Feb 9;282(6):3507-19. doi: 10.1074/jbc.M610141200. Epub 2006 Dec 11. J Biol Chem. 2007. PMID: 17158870 Free article.

10

Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer.

Gu J, Berman D, Lu C, Wistuba II, Roth JA, Frazier M, Spitz MR, Wu X. Gu J, et al. Among authors: wistuba ii. Clin Cancer Res. 2006 Dec 15;12(24):7329-38. doi: 10.1158/1078-0432.CCR-06-0894. Clin Cancer Res. 2006. PMID: 17189404

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

713 results

Search Page